Caris Life Sciences took a step to expand access to its blood-based genomic profiling assay by submitting an application to the New York State Department of Health (NYSDOH) for authorization to run Caris Assure on specimens from New York. Caris said the review will be conducted by the Wadsworth Center, initiating the state’s formal Clinical Laboratory Evaluation Program (CLEP) process. Separately, Guardant Health reported strong Q1 2026 revenue growth and lifted full-year guidance, driven by continued momentum in minimal residual disease testing and screening volume. The company highlighted volume expansion across Guardant360 Liquid and Guardant360 Tissue, including an upgrade that will add whole-transcriptome RNA testing as a volume catalyst. Together, the moves underscore how precision oncology platforms are pushing for reimbursement and geographic expansion while scaling assay demand through product updates and clinical adoption.